[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341464-105":59,"doc-detail-341464-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","the-prognostic-role-of-albumin-levels-in-lung-cancer-patients-receiving-third-line-or-advanced-immunotherapy-retrospective-study","The prognostic role of albumin levels in lung cancer patients receiving third-line or advanced immunotherapy - retrospective study","","Retrospective analysis evaluates whether baseline albumin (ALB) can predict treatment efficacy and survival in lung cancer patients receiving third-line or later immunotherapy. Data were collected from 250 patients treated with toripalimab or tislelizumab, using a median cut-off for ALB and multivariable statistical modeling to assess clinical factors. ALB showed little prognostic value in first- or second-line settings, but became significantly associated with outcomes beyond the second line, including improved disease control rate and overall survival.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-prognostic-role-of-albumin-levels-in-lung-cancer-patients-receiving-third-line-or-advanced-immunotherapy-retrospective-study/341464/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-prognostic-role-of-albumin-levels-in-lung-cancer-patients-receiving-third-line-or-advanced-immunotherapy-retrospective-study/341464.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main goal regarding albumin levels?","Question",{"text":112,"@type":113},"To identify factors influencing treatment outcomes and to determine whether baseline albumin (ALB) has prognostic value for efficacy and survival in patients receiving third-line or later immunotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was albumin (ALB) categorized for analysis?",{"text":117,"@type":113},"The median ALB value was used to create a cut-off, allowing continuous variables to be divided into groups for statistical comparison.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about ALB in different treatment lines?",{"text":121,"@type":113},"ALB had negligible prognostic relevance in patients receiving first- or second-line immunotherapy (P>0.05), but showed significant prognostic importance in patients treated beyond the second line (P=0.039).",{"name":123,"@type":110,"acceptedAnswer":124},"What were the key outcome associations in the third-line or later group?",{"text":125,"@type":113},"Higher baseline ALB correlated with a higher disease control rate and was associated with overall survival, indicating ALB as an independent predictor of OS in this setting.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},341464,1790635190,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","The prognostic role of albumin levels in lung cancer patients receiving third-line or advanced immunotherapy: a retrospective study  \nYanfei Chen1\\#, Tong Liu2,3,4\\#, Hui Feng5, Tiantian Liu6, Jing Zhang7, Jun Wang8, Jihong Lu9, Antonio Rossi10, Ivy Riano11, Pingping Hu2,3,4, Jiandong Zhang2,3,4  \n1Department of Oncology, Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Jinan, China; 2Department of Oncology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China; 3Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China; 4Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan, China; 5Department of Radiation Therapy, Linyi Cancer Hospital, Linyi, China; 6Department of Oncology, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China; 7Department of Childhood Health Development Center, Affiliated Central Hospital of Shandong First Medical University, Jinan, China; 8Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China; 9College of Clinical and Basic Medicine of Shandong First Medical University, Jinan, China; 10Oncology Centre of Excellence, Therapeutic Science & Strategy Unit, IQVIA, Milan, Italy; 11Section of Hematology and Medical Oncology, Dartmouth Cancer Center, Dartmouth Health, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA  \nContributions: (I) Conception and design: Tong Liu, P Hu; (II) Administrative support: P Hu, Jiandong Zhang; (III) Provision of study materials or patients: H Feng, J Wang; (IV) Collection and assembly of data: Tiantian Liu, J Lu; (V) Data analysis and interpretation: Tong Liu, Jing Zhang; (VI)  \nManuscript writing: All authors; (VII) Final approval of manuscript: All authors.  \n\\#These authors contributed equally to this work.  \nCorrespondence to: Pingping Hu, PhD; Jiandong Zhang, PhD. Department of Oncology, Shandong Provincial Qianfoshan Hospital, Shandong University, 16766 Jingshi Road, Jinan 250013, China; Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, China; Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan, China. [Email: hupingping0915@126.com](Email: hupingping0915@126.com); [zhangjd2233@126.com](zhangjd2233@126.com).  \nBackground: Immunotherapy functions by leveraging immunoregulation drugs to bolster the immune system’s capacity to identify and eliminate cancerous cells. In contrast to radiotherapy and chemotherapy, immunotherapy exhibits diminished side effects, heightened efficacy, and prolonged survival rates.  \nNevertheless, meticulous exploration into the determinants governing the advantageous effects of immunotherapy among patients who have previously undergone multiple prior therapies has yet to be conducted. Albumin (ALB) as a nutritional indicator has not been thoroughly studied for its prognostic effect on efficacy or survival. This study aims to identify factors that influence treatment outcomes among patients  \nundergoing third-line or later immunological therapies.  \nMethods: A cohort of 250 lung cancer patients undergoing toripalimab or tislelizumab immunotherapy was the focal point of data collection. The determination of the median value facilitated the establishment of a cut-off point, enabling the categorization of continuous variables. After data collection, a series of statistical analyses of various clinical factors at baseline were performed, including nonparametric tests, logistic regression, and Cox proportional risk modeling. The last follow-up was in May 2022. The primary study  \nendpoint was overall survival (OS) .  \nResults: A total of 250 patients were enrolled in the study, of which 129 patients received first-or secondline immunotherapy and 121 patients received third-line or subsequent immunotherapy. ","cbCaiqYBDqIB9vcr","https://ap.wps.com/l/cbCaiqYBDqIB9vcr","pdf",448764,11,"English","# Introduction\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What was the study’s main goal regarding albumin levels?\",\"answer\":\"To identify factors influencing treatment outcomes and to determine whether baseline albumin (ALB) has prognostic value for efficacy and survival in patients receiving third-line or later immunotherapy.\"},{\"question\":\"How was albumin (ALB) categorized for analysis?\",\"answer\":\"The median ALB value was used to create a cut-off, allowing continuous variables to be divided into groups for statistical comparison.\"},{\"question\":\"What did the results show about ALB in different treatment lines?\",\"answer\":\"ALB had negligible prognostic relevance in patients receiving first- or second-line immunotherapy (P\\u003e0.05), but showed significant prognostic importance in patients treated beyond the second line (P=0.039).\"},{\"question\":\"What were the key outcome associations in the third-line or later group?\",\"answer\":\"Higher baseline ALB correlated with a higher disease control rate and was associated with overall survival, indicating ALB as an independent predictor of OS in this setting.\"}]","The prognostic role of albumin levels in lung cancer patients receiving third-line or advanced immunotherapy - retrospective study | PDF",1790042008,28,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88589e920ebf8e94b5985560ec4019b4.webp",983,1287,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6343c80149622b1a2e4877d77b7af172.webp",982,1286,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7468b8c5ec034cf89a369b2c3339c7b4.webp",981,1284,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea92e06947888cb9a83adcb7aaa241ba.webp",980,1283]